

Dynamic Trans-rectal Sonography: A Valuable Tool for both Diagnosis and Tailoring Therapy for Urinary Incontinence after Prostate Cancer Treatment

Ju-Chuan Hu¹, Kun-Yuan Chiu¹, Shian-Shiang Wang¹, Chuan-Shu Chen¹, Kevin Lu¹, Jian-Ri Li¹, Fang-Tzu Kuo¹, Chin-Shan Chiang², Hann-Chorng Kuo³ 1 Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan. 2 Department of Rehabilitation, Taichung Veterans General Hospital, Taichung, Taiwan. 3 Department of Urology, Hualien Tzu Chi Hospital, Hualien, Taiwan



Hualien Tzu Chi Hospita

Introduction

Current guidelines recommend definitive treatments for prostate cancer, including radical prostatectomy, radiation therapy, and focal therapy like High-Intensity Focus Ultrasound (HIFU). However, these treatments often result in distressing urinary incontinence. Factors contributing to post-prostatectomy incontinence include age, urethral length, prior procedures, nerve preservation, and surgical techniques. Yet, these anatomical factors can change after surgery, making a single strategy ineffective.

Pelvic floor muscle training (PFMT) is crucial for managing postprostatectomy incontinence (PPI). However, conflicting PFMT methods yield differing results due to variations in study approaches and factors such as incontinence severity. Urodynamic studies, while helpful, are too invasive for initial diagnosis, necessitating a less invasive diagnostic tool for tailored PFMT.

This study employs post-operative dynamic trans-rectal sonography to assess stress urinary incontinence (SUI) components and severity, guiding personalized PFMT. This approach, less invasive than alternatives, can customize treatment for urinary incontinence after prostate cancer procedures.

Table 1. The characteristics of the patients	
	Patients with UI received PFMT (n=10)
Age when received prostate treatment (year-old)	66 (62-74)
Age when received PFMT (year-old)	66.5 (66-75.8)
Period from prostate treatment to intensive PFMT(mont	10 (3-24)
Prostate size (gm)	33.5 (23.8-40.9)
PSA when diagnosed with prostate cancer (ng/ml)	9.1 (5.4-11.0)
Gleason score	
GS=7	6 (60%)
GS=8	2 (20%)
GS=9	2 (20%)
T stage	0 (000)
c12c (in HIFU patients)	2 (20%)
p12	6 (60%)
pisa Turo of definite treatment for prestate concer	2 (20%)
Type of definite treatment for prostate cancer	C (CON))
Robotic radical prostatectomy-Conventional	0 (00%)
Robotic radical prostatectomy-Retzius sparing	2 (20%)
RIFU Significant improved LIL ofter DEMT	2 (20%)
Significant improved of after PFMT	7 (70%)
Baseline functional transrectal sono	
Pelvic floor movement in stress test (cm)	0.8 (0.6-1.2)
Severity of urethral imcompetence	0.0 (0.0-1.2)
Mild	5 (50%)
Moderate	2 (20%)
Severe	3 (30%)
ICIO-SE	0 (00 /0)
Baseline ICIO-SE	
Q3 (frequency of UI)	5 (4-5)
Q4 (severity of UI)	6 (4-6)
Q5 (QoL of UI)	8 (7-10)
Total score	19 (15-21)
Post-PFMT ICIQ-SF	
Q3 (frequency of UI)	4 (4-4)
Q4 (severity of UI)	4 (2-4)
Q5 (QoL of UI)	6 (5-8)
Total score	16 (11-17)
Change of ICIQ-SF	, , , , , , , , , , , , , , , , , , ,
Q3 (frequency of UI)	-1 (-1 to 0)
Q4 (severity of UI)	-2 (-2 to 0)
Q5 (QoL of UI)	-2 (-3 to -1)
Total score	-4 (-8 to -1)
OAB/UUI	· · ·
Basline OAB/UUI	6 (60%)
Post-PFMT OAB/UUI	3 (30%)
Pelvic floor evaluation	
Baseline pelvic floor parameter	
IAS length (cm)	3 (2.8-3.1)
Oxford muscle power	2 (2-2.5)
Manometry-maximum (mmHg)	20.2 (16.3-21.4)
Manometry-mean (mmHg)	2.5 (1.8-3.6)
After intensive PFMT	
IAS length (cm)	3.5 (3.3-3.6)
Oxford muscle power	3 (2.5-3)
Manometry-maximum (mmHg)	33.2 (28.9-56.7)
Manometry-mean (mmHg)	7.4 (5.1-10.2)
Change of Pelvic floor parameter	
IAS length (cm)	0.7 (0.5-0.8)
Oxford muscle power	1 (0.5-1)
Manometry-maximum	17.1 (8.7-33.4)
Manometry-mean	3.2 (2.9-6.7)

Methods and Materials

Patients with distressing urinary incontinence post-prostate cancer treatment were referred to our Uro-rehabilitation team for intensive PFMT. This prospective clinical trial enrolled consecutive patients from January to March 2023. Dynamic trans-rectal sonography assessed pelvic floor support and urethral competence during rest, cough, and strain. Additional evaluations included anal manometry and other pelvic floor parameters. The standard PFMT program involved six weekly sessions of vision-guided biofeedback and trans-anal electrical stimulation. Incontinence severity was gauged with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) and daily pad count. Patient profiles were obtained through chart review.

Results

Ten patients completed six intensive PFMT sessions during the study period. Patient characteristics are outlined in Table 1. Ultrasound results were divided into two stress urinary incontinence components: intrinsic sphincteric deficiency (ISD) presence and impaired pelvic floor support degrees (Fig. 1). Median age at definitive prostate therapy was 66 years (IQR 62-74), with a median time of 10 months (IQR 3-24 months) from prostate surgery to PFMT. Among them, eight patients underwent robotic radical prostatectomy (six conventional, two Retziussparing), and the remaining two received HIFU therapy.

Fig 1. Different phenotypes in the dynamic trans-rectal sonography amoung patients with post-prostatectomy incontinence



Values are expressed as median (IQR) or number (percentage)

Abbreviation: **GS**, Gleason Score; **HIFU**, High Intensity Focus Ultrasound therapy; **IAS**, internal anal sphicter length; ICIQ-SF, International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form; ISD, intrinsinc sphincter deficiency

Discussion

Of the **seven** patients who experienced a remarkable reduction in daily pad usage (≥ 3pads/day), three achieved **complete** continence without protective pads. Their baseline sonographic findings showed less intrinsic sphincteric deficiency (ISD) severity and impaired pelvic floor support.

However, the remaining **four** patients still needed 1-3 pads daily after completing six sessions of intensive PFMT. Their baseline dynamic transrectal ultrasound showed more severe ISD and pelvic floor hypermobility in these four patients, which helped predict the need for prolonged pelvic floor rehabilitation and further treatment when patient counseling before initiation of intensive PFMT.

Among the **three** patients who continued using > 4pads daily, **one** still had severe ISD due to HIFU and salvage radiation therapy. The other two patients who still had severe PPI showed much-improved ISD and pelvic floor support in dynamic sonography but had urge urinary incontinence (UUI). Video-urodynamic tests confirmed no more SUI but marked **detrusor overactivity** with UUI in these two patients, and further strategies for UUI were offered to them.

Conclusions

Post-prostatectomy incontinence is a complex condition that can be caused by intrinsic sphincteric deficiency, impaired pelvic floor support, and urge urinary incontinence. Dynamic trans-rectal sonography is a feasible and less invasive tool for identifying the specific components of **PPI** and providing valuable information for **developing individualized** continence programs.

References

- 1. How can we prevent postprostatectomy urinary incontinence by patient selection, and by preoperative, preoperative, and postoperative measures? International Consultation on Incontinence-Research Society 2018. Neurourol Urodyn. 2019;38 Suppl 5:S119-S126.
- 2. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev. 2015;1(1):CD001843.